Copyright
©The Author(s) 2022.
World J Clin Cases. Feb 16, 2022; 10(5): 1580-1585
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1580
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1580
Time | Syndrome or treatment | Oncologic response |
October 2017 | Fever (maximum 41 °C), palpitation, nausea and cough for 1 mo | |
October 2017 | Diagnosed as medium differentiated adenocarcinoma lung cancer with EGFR and ALK gene mutations negative by CT-guided puncture biopsy | |
November 2017 | Considered have primary CRS with related to lung cancer, and treated with DXM, gamma globulin and other supporting treatments. The patient stopped fever soon | |
December 2017 to February 2018 | Four cycles of chemotherapy with pemetrexed + cisplatin | PR |
June 11, 2018 | Recurrent fever for 10 d with CT showed tumor progressed again | PD |
July 2018 to August 2018 | Radiotherapy then stated to take | PR |
August 2018 | Anlotinib | PR |
May 2019 | Nivolumab for 5 cycles | PR |
April 2019 | Died | PD |
- Citation: Deng PB, Jiang J, Hu CP, Cao LM, Li M. Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report . World J Clin Cases 2022; 10(5): 1580-1585
- URL: https://www.wjgnet.com/2307-8960/full/v10/i5/1580.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i5.1580